69 related articles for article (PubMed ID: 19420948)
21. [Buprenorphine and methadone to opiate addicts--a randomized trial].
Kristensen Ø; Espegren O; Asland R; Jakobsen E; Lie Ø; Seiler S
Tidsskr Nor Laegeforen; 2005 Jan; 125(2):148-51. PubMed ID: 15665884
[TBL] [Abstract][Full Text] [Related]
22. Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status.
Kornør H; Waal H; Sandvik L
Drug Alcohol Rev; 2007 Mar; 26(2):135-41. PubMed ID: 17364848
[TBL] [Abstract][Full Text] [Related]
23. [French nationwide survey of abstinence-oriented treatments in opiate-addicted patients. Results at 12 months].
Vignau J; Boissonnas A; Tignol J; Millot Y; Mucchielli A
Ann Med Interne (Paris); 2003 Nov; 154 Spec No 2():S23-32. PubMed ID: 14760224
[TBL] [Abstract][Full Text] [Related]
24. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
Petry NM; Bickel WK; Badger GJ
Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
[TBL] [Abstract][Full Text] [Related]
25. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
[TBL] [Abstract][Full Text] [Related]
26. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
[TBL] [Abstract][Full Text] [Related]
27. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
[TBL] [Abstract][Full Text] [Related]
28. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
Marsch LA; Bickel WK; Badger GJ; Jacobs EA
Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
30. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
31. [Use of buprenorphine as a substitute treatment for opiate dependence in the Toxicology Clinics--introductory clinical report].
Radomska M; Pach J; Chrostek Maj J
Przegl Lek; 2001; 58(4):351-3. PubMed ID: 11450367
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine replacement therapy: a confirmed benefit.
Prescrire Int; 2006 Apr; 15(82):64-70. PubMed ID: 16604748
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
34. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients.
Soyka M; Apelt SM; Lieb M; Wittchen HU
J Clin Psychopharmacol; 2006 Dec; 26(6):657-60. PubMed ID: 17110826
[TBL] [Abstract][Full Text] [Related]
35. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
36. Exposure to opioid maintenance treatment reduces long-term mortality.
Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
[TBL] [Abstract][Full Text] [Related]
37. [Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice].
Dupouy J; Bez J; Barsony J; Oustric S; Lapeyre-Mestre M
Therapie; 2013; 68(3):155-61. PubMed ID: 23886460
[TBL] [Abstract][Full Text] [Related]
38. Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS.
Polonsky M; Azbel L; Wickersham JA; Taxman FS; Grishaev E; Dvoryak S; Altice FL
Drug Alcohol Depend; 2015 Mar; 148():47-55. PubMed ID: 25620732
[TBL] [Abstract][Full Text] [Related]
39. A national study of a telephone support service for patients receiving office-based buprenorphine medication-assisted treatment: study feasibility and sample description.
Ruetsch C; Cacciola J; Tkacz J
J Subst Abuse Treat; 2010 Dec; 39(4):307-17. PubMed ID: 20728299
[TBL] [Abstract][Full Text] [Related]
40. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.
Haddad MS; Zelenev A; Altice FL
Drug Alcohol Depend; 2013 Jul; 131(1-2):127-35. PubMed ID: 23332439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
